GlassScriptPhysician profile
Denisa K Russell
NPI 1750628798
$11,250.16
in general payments reported to CMS, 2019-2025
33 companies · $3,189 in 2025
The $3,189 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,150 · 2022: $1,277 · 2023: $2,850 · 2024: $2,784 · 2025: $3,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,657 · Consulting Fee: $1,775 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,657.35 |
| Consulting Fee | $1,775.00 |
| Education | $391.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,519.72 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,185.09 | 2022-2025 | Arazlo, Siliq, Cabtreo |
| Abbvie INC. | $1,046.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $813.23 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $671.27 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $667.43 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $663.96 | 2021-2025 | |
| Lilly USA, LLC | $653.25 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $531.75 | 2021-2025 | Tremfya, Stelara, Simponi |
| Allergan, INC. | $477.08 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $347.00 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $334.38 | 2021-2025 | |
| Galderma Laboratories, L.P. | $267.07 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Journey Medical Corporation | $250.00 | 2021 | |
| Amgen INC. | $240.46 | 2024-2025 | Otezla, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $228.90 | 2022-2024 | Vtama |
| Genzyme Corporation | $225.59 | 2023-2025 | |
| Ucb, INC. | $184.03 | 2021-2025 | Bimzelx |
| Organon LLC | $176.59 | 2025 | Vtama |
| Incyte Corporation | $168.68 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $112.77 | 2023-2025 | |
| Merz North America, INC. | $93.24 | 2022-2025 | |
| Almirall LLC | $89.76 | 2022-2024 | Klisyri, Seysara |
| Novo Nordisk INC | $50.03 | 2023-2024 | Rybelsus, Ozempic |
| Kerecis Limited | $48.55 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Biofrontera INC. | $44.74 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Angiodynamics, INC. | $40.56 | 2023 | Venacure 1470 Pro |
| Dermira, INC. | $33.66 | 2021 | |
| Botanix Sb INC | $24.00 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $17.85 | 2021 | |
| Tactile Systems Technology INC | $16.01 | 2023 | Entre Plus, Flexitouch Plus |
| Cipher Pharmaceuticals US LLC | $15.59 | 2025 | Spinosad, Natroba |
| Nabriva Therapeutics, Plc | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denisa Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.